Post by
Jon9800 on Jun 24, 2022 9:45am
$HMTXF get backs all its intellectual property
Hemostemix is now in possession of all of its intellectual property, including all HS 12-01 Phase II clinical trial data, all historical data from Hemostemix Israel, and the randomization tables that are required to analyze the North American and South African ACP-01 clinical trial data.